Connect with us

News

FDA Approves Israeli Cancer-Freezing Technology

IceCure’s cancer-freezing technology relies on an innovative process referred to as cryoablation therapy.

Published

on

fda approves israeli cancer-freezing technology
Shutterstock

Israeli healthtech companies and researchers have developed many life-saving technologies, some of which are now used in hospitals around the world. One highly promising medical technology has just been approved by the United States Food and Drug Administration (FDA) after demonstrating its ability to eliminate tumors using new cancer-freezing technology.

The groundbreaking technology comes from a healthtech company called IceCure. The company was founded in 2006, and it’s currently headquartered in the coastal city of Caesarea, Israel.

IceCure’s cancer-freezing technology relies on an innovative process referred to as cryoablation therapy. The goal of cryoablation is to insert a hollow needle into the breast until the tumor is reached. Liquid nitrogen is then precisely applied directly into a tumor to kill the abnormal tissue by freezing it at a very low temperature of -170°C (-274 F).

“We are basically covering the tissue with an ice ball. No tissue can survive such a low temperature,” explained Tlalit Bussi Tel-Tzure, vice president of business development and global marketing at IceCure. “Once the tissue is dead, it will dissolve in the body in a natural process and be absorbed in the body in a couple of weeks.”

The technology has already proved to be extremely successful when it comes to destroying kidney tumors, demonstrating perfect efficiency. Its main advantage is the fact that it can be carried out either at a doctor’s office or an outpatient facility thanks to its minimally invasive nature. The entire procedure can take less than one hour from start to finish, and it doesn’t leave any lasting physical mark on the body.

Also Read: Israelis Have Successfully Grown Mouse Embryos In Artificial Wombs

“Our main vision is to become the gold standard in breast cancer treatment,” said Eyal Shamir, CEO of IceCure Medical. “Most of the cases where you have good early detection are small tumors, considered early stage, and the only treatment available today is surgery.”

IceCure isn’t the only company exploring the application of cryoablation for treating breast cancer. There’s also California-based Sanarus Technologies, which has recently completed a clinical trial in the United States.

Advertisement

📢 Get Exclusive Monthly Articles, Updates & Tech Tips Right In Your Inbox!

JOIN 17K+ SUBSCRIBERS

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

News

Initial Trials Of Dubai’s Driverless Evocargo Trucks Completed

Testing was announced on July 17, and the completion is a major milestone towards upgrading the region’s logistics infrastructure.

Published

on

initial trials of dubai's driverless evocargo trucks completed
Dubai Media Office

A Dubai-based company has completed the initial trials for the UAE’s first driverless trucks. The groundbreaking achievement by Evocargo, partnering with Dubai South, took place at Dubai South Logistics District, and marked a significant step towards incorporating autonomous technologies into the region’s wider logistics infrastructure.

Announced on Wednesday, July 17th, the trials featured the Evocargo N1 unmanned electric truck navigating a predetermined route within a controlled setting. The test involved interactions with common road obstacles such as cars, trucks, and pedestrians, aiming to evaluate the vehicle’s hardware and software reliability, accident prevention systems, and overall readiness for public road use.

Officials were keen to highlight that this accomplishment aligns with the UAE’s ambitious strategy to position itself as a global leader in innovation and technology adoption. The country aims to have 25% of all transportation in Dubai autonomous by 2030, underscoring its commitment to revolutionizing the logistics sector using advanced technologies.

Mohsen Ahmad, CEO of the Logistics District at Dubai South, emphasized the importance of the collaboration with Evocargo in enhancing the region’s logistics capabilities. He noted that autonomous vehicles are set to increase efficiency, reduce carbon emissions, and establish a sustainable logistics infrastructure that will benefit both Dubai and the wider UAE.

Also Read: Riyadh Developers Reveal New 45,000-Seat Murabba Stadium

Ahmed Al-Ansi, CEO of Evocargo Autonomous Logistic Services, also expressed optimism that the trials will draw new customers and investments across the Gulf Cooperation Council (GCC) countries. The partnership aims to lead in innovative tech solutions, further establishing the UAE as a pioneer in autonomous transportation.

The successful completion of the trials marks a crucial step towards realizing the UAE’s vision for a technologically advanced and sustainable future in which autonomous vehicles are expected to play a pivotal role in global logistics.

Continue Reading

#Trending